Calls
At ECRIN, we can provide support to investigators in preparing proposals for multinational clinical study funding, provided the project meets ECRIN’s eligibility criteria.
For more information on how ECRIN can support you in the preparation of these calls, see Clinical Trials Preparation and contact your local European Correspondent.
For more information and guidance on Horizon Europe funding schemes and opportunities, you are encouraged to contact your National Contact Point (NCP). Additional details on funding opportunities and events under Cluster 1 – Health are also available on the HNN3 network website, which brings together NCPs in the health area.
The calls listed below may be relevant for your applications for clinical trials / clinical research in various fields. In the News section of our website, you can also find additional information on calls on diverse topics other than clinical trials.
Discover the European funding programs for multinational clinical trials.
Call Launch :
Deadline :
Deadline 2 :
Description :
IHI call 10 - a standard, two-stage call
IHI call 10 will be a standard, two-stage call for proposals with the following topics
- Digital label: one source of comprehensive information for medical technology products
- Enabling and safeguarding innovation in secondary use of health data in the European Health Data Space (EHDS)
- Per- and Poly-fluoroalkyl substance (PFAS) exposure, emissions, and end of life management in the healthcare sector
Read the full call text:
Links :
Call Launch :
Description :
IHI call 9 – a single-stage, applicant driven call
IHI call 9 will be a single-stage, applicant-driven call with five topics aligned with the five specific objectives set out in the IHI Strategic Research and Innovation Agenda (SRIA). For this call, the IHI want applicants to explore the SRIA and identify untapped opportunities that could be transformed into public-private projects through IHI.
Proposals will still have to adhere to the philosophy of IHI. In other words, they will have to: address an unmet public health need; require a large-scale, ambitious, cross-sector, public-private partnership; have clearly-described impacts on society, the economy and science; take account of the pre-competitive nature of IHI projects.
The call will open in early 2025, date TBD.
Answers to FAQs can be found here.
Links :
Call Launch :
Deadline :
Deadline 2 :
Description :
The Partnership “Fostering a European Research Area for Health” (ERA4Health) aims at establishing a flexible and effective coordination between funding organisations in the European Research Area (ERA) in priority areas addressing European Public Health Needs.
This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming. Under this umbrella, ERA4Health is glad to pre-announce the launch of a first Joint Transnational Call (JTC) in multi-country Investigator-Initiated Clinical Studies (IICS) on “Fostering Pragmatic Comparative-Effectiveness Trials in Non-communicable Diseases” (EffecTrial).
The aims of the call are:
- To support randomised, interventional and pragmatic comparative-effectiveness multi-country Investigator-Initiated Clinical Studies (IICS).
- To encourage and enable transnational collaboration between clinical/public health research teams (from hospital/ public health, healthcare settings and other healthcare organisations) that conduct comparative-effectiveness multi-country IICS.
The project duration is 48 months and it is co-funded by Horizon Europe.
📅 Upcoming Info Day: 27 November from 14h30–16h30 CET (details coming soon).
More information available here
Call Launch :
Description :
The Anticancer Fund announces the launch of a call for research projects in the treatment of rare cancers, together with five other organisations. It is the second time this consortium, ATTRACT, funds clinical trials to stimulate the development of better treatments for rare cancer patients.
ATTRACT is the first international initiative to accelerate drug development for rare cancers by funding cross-border clinical academic research. Building on the success of the first edition (ATTRACT 2023), we are excited to organise a second call for projects in September 2024. We invite European researchers and clinicians from different countries to unite and collaborate in setting up late phase (phase 2/3) international clinical trials that aim to advance the development of better drug therapy for rare cancer patients.
The Anticancer Fund announces the launch of a call for research projects in the treatment of rare cancers, together with five other organisations. It is the second time this consortium, ATTRACT, funds clinical trials to stimulate the development of better treatments for rare cancer patients.
ATTRACT is the first international initiative to accelerate drug development for rare cancers by funding cross-border clinical academic research. Building on the success of the first edition (ATTRACT 2023), we are excited to organise a second call for projects in September 2024. We invite European researchers and clinicians from different countries to unite and collaborate in setting up late phase (phase 2/3) international clinical trials that aim to advance the development of better drug therapy for rare cancer patients.
Links :